FluxMPS™ Minimum Essential Medium Eagle (MEM) w/ Earle's salts, NEAA: 1X Liquid

FluxMPS™ Minimum Essential Medium Eagle (MEM) w/ Earle's Salts, NEAA, 1X Liquid

FluxMPS™ MEM with Earle's Salts and Non-Essential Amino Acids (NEAA) is a Microfluidics Suitable, ultra-filtered 1X liquid cell culture medium engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. Processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used for conventional filtration — it is released at an endotoxin specification of less than 0.05 EU/mL with sub-mycoplasma-range final filtration for microchannel-safe performance.

• Quadruple-stage filtration train: 0.1 µm prefilter → 0.04 µm final filter → 0.1 µm prefilter → 0.04 µm final filter, reaching a 0.04 µm final cut-off
• Endotoxin release specification: less than 0.05 EU/mL, verified by LAL assay per USP <85>
• Earle's balanced salt formulation with a complete Non-Essential Amino Acid supplement (Gly, L-Ala, L-Asn, L-Asp, L-Glu, L-Pro, L-Ser) for broader cell line support
• Sodium bicarbonate-buffered (2,200 mg/L) with phenol red pH indicator; formulated for a standard 5% CO₂ incubator atmosphere
• Manufactured under an ISO 13485:2016 quality management system with a per-batch Certificate of Analysis
• Glucose (1,000 mg/L) and sodium pyruvate (110 mg/L) included for standard monolayer and 3D culture energy metabolism
• pH, sodium bicarbonate level, glucose concentration, HEPES buffering, and NEAA composition available on request

Engineered where standard MEM fails

Conventional 0.22 µm-filtered MEM retains subvisible particles, mycoplasma-range contaminants, and endotoxin fragments that can compromise organ-on-a-chip sensors, clog microfluidic channels, and add background to metabolic assay signals. FluxMPS™ MEM with Earle's Salts and NEAA is built against these failure modes with a validated four-stage filtration architecture, delivering a microchannel-safe, ultra-clean medium.^[1,2]

Quadruple-stage filtration system

FluxMPS™ MEM with Earle's Salts and NEAA is filtered through a validated four-stage cascade reaching a 0.04 µm final pore size, engineered for microchannel-safe performance in MPS, organ-on-a-chip, and precision microfluidic perfusion systems.

1. 1

   0.1 µmPrefiltration I

   Removes gross aggregates, large particles, and precipitates that would rapidly blind downstream nano-filters, extending cascade filter life and maximizing throughput.

2. 2

   0.04 µmFinal filtration I

   First 0.04 µm pass; retains fine particulates and mycoplasma-range organisms (0.2–0.3 µm diameter) that a 0.22 µm filter would not capture.

3. 3

   0.1 µmPrefiltration II

   A second, dedicated 0.1 µm prefilter protects the second 0.04 µm cartridge, preserving flow and filtration integrity through the final polish.

4. 4

   0.04 µmFinal filtration II — Polish

   Ultimate 0.04 µm polishing filter immediately before aseptic fill & finish, delivering the lowest achievable particulate count for microfluidic channel safety.

Designed for the most demanding cell culture systems

FluxMPS™ MEM with Earle's Salts and NEAA supports a broad spectrum of research applications, from classical monolayer culture of HeLa and Vero cells to advanced organ-on-a-chip perfusion, iPSC-derived multi-lineage co-cultures, and biosensor-integrated systems. Its ultra-clean purity architecture makes it well suited wherever conventional MEM introduces particle noise or mycoplasma risk.^[4,5]

Automated Bioreactors & Robotics

For high-throughput automated perfusion bioreactors and liquid-handling robotics, an optional 0.01 µm (10 nm) ultra-filtered MPS Grade variant of FluxMPS™ MEM with Earle's Salts and NEAA is available. This next-tier grade is engineered for precision perfusion systems where valve and sensor longevity are paramount.

• Total Particulate Exclusion: 10 nm filtration removes nano-aggregates that elude 0.04 µm filters, protecting microvalves and pressure transducers.
• Valve & Sensor Protection: Reduces particle accumulation on solenoid valve seats and optical flow sensors, extending maintenance intervals in continuous-perfusion rigs.
• Extended Perfusion Stability: Reduced bioburden and particulate load support multi-week uninterrupted perfusion runs in closed-loop bioreactor systems.

Inquiry Required: The 0.01 µm (10 nm) MPS Grade variant is a custom/bulk order configuration. Contact support@diagnocine.com to request this grade for your automated system.

Complete specification matrix

All parameters are validated per batch prior to release. Certificate of Analysis (CoA) available upon request at support@diagnocine.com.

Full composition (mg/L)

MEM with Earle's Salts and NEAA: 37 ingredients verified per lot with CAS numbers. The AMINO ACIDS tab includes both essential amino acids (EAA) and Non-Essential Amino Acids (NEAA) as one combined group per the source composition table.

Manufacturing & compliance standards

Every batch of FluxMPS™ MEM with Earle's Salts and NEAA is manufactured and released under a fully validated ISO 13485:2016 quality management system, with documented micro-batch traceability from raw material receipt through final fill & finish.

How FluxMPS™ MEM + NEAA compares

A head-to-head assessment of FluxMPS™ MEM with Earle's Salts and NEAA against conventional 0.22 µm-filtered MEM alternatives commonly used in cell culture laboratories.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Answers to the most common questions about FluxMPS™ MEM with Earle's Salts and NEAA, its filtration, formulation, and compatibility with advanced culture platforms.

Supporting literature

Curated peer-reviewed references supporting the use of Microfluidics Suitable, ultra-filtered media in organ-on-a-chip, microfluidic, and advanced cell culture systems.

1. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
2. Bhatt DL, Bhatt AK, Wiegmann B, et al. Organ-on-a-chip platforms for drug testing: bridging the gap between in vitro and in vivo models. Nat Rev Drug Discov. 2022;21:665–687.doi:10.1038/s41573-022-00486-2
3. Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23:467–491.doi:10.1038/s41576-022-00466-9
4. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114–118.PMCID: PMC3966166
5. Young EWK, Beebe DJ. Fundamentals of microfluidic cell culture in controlled microenvironments. Chem Soc Rev. 2010;39(3):1036–1048.doi:10.1039/b909900j
6. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
7. Zhu J, Shyy JY. Endothelial mechanobiology in arterial disease — the role of shear stress and microfluidic models. J Biomech. 2020;109:109–119.doi:10.1016/j.jbiomech.2020.109898
8. Prantil-Baun R, Novak R, Das D, et al. Physiologically based pharmacokinetic and pharmacodynamic analysis enabled by microfluidically linked organs-on-chips. Annu Rev Pharmacol Toxicol. 2018;58:37–64.doi:10.1146/annurev-pharmtox-010716-104748
9. Eagle H. Amino acid metabolism in mammalian cell cultures. Science. 1959;130(3373):432–437.doi:10.1126/science.130.3373.432
10. Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–845.doi:10.1038/nrm2236